Drug Trial Radar · NCT07922330
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
330
Planned (sponsor's estimate)
Start
Jan 4, 2027
Primary completion
Sep 15, 2028
Study completion Sep 15, 2028
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Nov 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy and safety of AZD6234 compared with placebo in adults who are overweight or obese, with or without type 2 diabetes mellitus.
Conditions
- Obesity
- Overweight
- Type 2 Diabetes Mellitus
Interventions
AZD6234Drug
administered once weekly.
PlaceboDrug
Matching placebo administered once weekly.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change in body weight from baseline at Week 64Time frame: up to 64 weeks
- Number of participants achieving at Least a 5% Reduction in Body Weight From Baseline at Week 64Time frame: up to 64 weeks
Locations
34 sites in 2 countries. Site status is shown where the registry gives one.
Research Site
Beijing, China
Research Site
Bozhou, China
Research Site
Cangzhou, China
Research Site
Changzhou, China
Research Site
Chongqing, China
Research Site
Daqing, China
Research Site
Ganzhou, China
Research Site
Guangzhou, China
Research Site
Guangzhou, China
Research Site
Jiaxing, China
Research Site
Jinan, China
Research Site
Jinan, China
Research Site
Liuzhou, China
Research Site
Luoyang, China
Research Site
Luzhou, China
Research Site
Sanya, China
Research Site
Shanghai, China
Research Site
Shanghai, China
Research Site
Shanghai, China
Research Site
Shenyang, China
Research Site
Shenyang, China
Research Site
Shiyan, China
Research Site
Suzhou, China
Research Site
Wuhan, China
Research Site
Xi'an, China
Research Site
Xuancheng, China
Research Site
Yuncheng, China
Research Site
Zhengzhou, China
Research Site
Ansārinagar, India
Research Site
Calicut, India
Research Site
Kolkata, India
Research Site
Ludhiana, India
Research Site
Meerut, India
Research Site
Surat, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.